November 2023

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medi

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: